Lipids are circulating as lipoproteins, consisting of unesterified cholesterol, triglycerides, phospholipids, and protein. There are five major lipoproteins in blood: (1) chylomicrons; (2) very low-density lipoprotein (VLDL); (3) intermediate-density lipoprotein (IDL); (4) low-density lipoprotein (LDL); and (5) high-density lipoprotein (HDL). Each of these classes of lipoproteins transports cholesterol and triglyceride to its designated destinations.
The level of cholesterol plays a vital role in cardiovascular diseases process. A high level of lipids, including cholesterol and triglycerides in the serum, which also termed as hyperlipidemia, leads to a higher risk of developing atherosclerotic cardiovascular disease (CVD). Clinically, obtaining a lipid profile assists in the screening, diagnosing, and managing diseases. Here, we will discuss the indications for testing, the role of lipid profiles, and the relevant health care issues. Generally, a lipid profile or lipid panel consists of the following,
Cholesterol level measurement is from serum. A non-fasting lipid test can be done anytime without fasting; a fasting lipid test requires a 12-hour fast except for water. Total and HDL cholesterol are measured directly from serum. First developed in the 1960s, Friedewald equation has been used widely to estimate LDL-C which is (total cholesterol) – (high-density lipoprotein cholesterol [HDL-C]) – (triglycerides/5) in mg/dL for research as well as clinical purpose. A fixed factor of 5 for the ratio of fasting triglyceride level(up to 4.5mmol/l ) to very low-density lipoprotein cholesterol(TG: VLDL-C) is the assumption from the equation. Optimizing LDL-C level has been the main target for current guidelines, including the European Society of Cardiology, European Atherosclerosis Society, and the American Heart Association and American College of Cardiology. There are several limitations of the Friedewalk equation as follows:
In an extensive cross-sectional analysis, Martin SS et al. proposed a novel calculation that is more accurate than the Friedewald equation regardless of fasting/nonfasting blood samples.Fasting or non-fastingWhile fasting LDL-C is still the standard for initiating lipid-lowering therapy, there has been a heated debate over fasting or non-fasting lipid profile among specialists. The rationale behind the discussion of fasting or non-fasting is because the triglycerides level can be affected by the last intake and the limitations of the Friedewald equation per se. Advantages of the non-fasting lipid profile are its accessibility clinically, simplicity for both patients and medical practitioners; whereas the fasting lipid profile is inconvenient for patients and clinicians as it requires an additional visit. Also, the accuracy of the fasting lipid profile depends on patients' compliance.Many current guidelines propose that nonfasting LDL-C holds similar significance to that of fasting LDL-C. A fasting lipid panel is a strong recommendation for patients with type 2 diabetes, obesity, medications that may affect lipid levels, such as thiazides and beta blockers, and excessive intake of alcohol. Apolipoproteins
The 2010 American College of Cardiology Foundation/American Heart Association guideline does not recommend measurement of apolipoproteins, size of lipid particles, and density for cardiovascular risk assessment. (Level III)
Indications for screening or obtaining lipid profile varies between adults and children.
DyslipidemiasPrimary disorders of lipid metabolism such as familial hypercholesterolemia (FH), chylomicronemia, familial combined hyperlipidemia, familial dysbetalipoproteinemia classify according to Fredrickson phenotype. Secondary dyslipidemia can result from diabetes mellitus, hypothyroidism, obstructive liver diseases, chronic renal failure, drugs that increase LDL-C including retinoids, cyclosporine A, and phenothiazines and drugs that decrease HDL-C including progestins, androgens, beta-blockers, and anabolic steroids.Based on the types of lipid abnormalities, dyslipidemias can be categorized into high total cholesterol (TC), High low-density lipoprotein cholesterol (LDL-C), High non-high-density lipoprotein cholesterol (non-HDL-C), High triglycerides (TG), and Low high-density lipoprotein cholesterol (HDL-C). According to the Adult Treatment Panel III (ATP III), the standard levels per guideline as following:
Metabolic syndrome There are five definitions of the metabolic syndrome:
Among these, The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) is the most widely used. Parameters for the definitions of metabolic syndrome are triglycerides, HDL cholesterol, glucose, hypertension, and obesity, and metabolic syndrome is diagnosed when three or more the followings are abnormal:
Atherosclerotic Cardiovascular disease (ASCVD)
Atherosclerosis is the major culprit in most of the coronary heart disease. Lipids and lipoproteins are established risk factors for developing atherosclerotic cardiovascular diseases(ASCVD). Large clinical trials reported lipid-lowering therapy to reduce the risk of ASCVD events.
Several factors are taken into account in 10-year risk cardiovascular assessment as following,
The 10-year risk for ASCVD falls into the following categories:
Risk-enhancing factors such as family history of premature ASCVD, metabolic syndrome, chronic kidney disease, premature menopause, chronic inflammatory disorders, high-risk ethnic groups (e.g., South Asian), persistent elevations of LDL-C greater than or equal to 160 mg/dL or triglycerides greater than or equal to 175 mg/dL, high-sensitivity C-reactive protein greater than or equal to 2.0 mg/L, and ankle-brachial index less than 0.9.
For dyslipidemia, obtaining a detailed family history is crucial. By identifying family members with any abnormal deposits of cholesterol in the skin or eyes, premature CHD, or those who have elevated cholesterol during childhood assist in establishing a diagnosis. Perform physical examination with attention to abnormal deposits of cholesterol in the skin or eyes, such as tendon xanthomata which mostly present in the Achilles tendons and dorsum of the hands, and xanthelasmas, which are soft and yellow plaques that often present on the eyelids. Fasting lipid profile revealed the majority of the abnormalities. However, an evaluation for causes resulted in secondary hyperlipidemia is warranted. The clinician can offer genetic testing of LDLR, APOB, and PCSK9 gene mutations, even though the benefits are still not well-established.
First and foremost, it is essential to educate individuals on a heart-healthy lifestyle. LDL-C is one of the major culprits in the development of atherosclerotic heart disease. The target level of LDL-C is between 50 to 70mg/dl to prevent plaque formation in the blood vessels. Patients should undergo evaluation for 10-year risk and those with more than 10 percent risk; guidelines strongly recommend statin therapy. Low levels of HDL-C are related to an increased risk of CVD; however, according to recent studies, HDL-C raising therapy showed no clinical benefit; therefore, routine use is not recommended.
Primary prevention recommendations for adults age between 40 to 75 years old With an LDL Level of 70 to 189 mg/dL. High levels of low-density lipoprotein-cholesterol (LDL-C) and low levels of high-density lipoprotein cholesterol (HDL-C) are risk factors for coronary heart disease. Large clinical trials have shown that lowering LDL-C levels significantly reduce cardiovascular events and mortality rate; whereas, according to current consensus, HDL-C is not a target for primary prevention in coronary artery diseases(CAD). Nevertheless, recent studies proposed the prognostic value of serum cholesterol efflux capacity in patients with coronary artery disease.
According to the 2018 Guideline on the Management of Blood Cholesterol,, clinicians should target at lowering LDL-C levels by more than 50% with maximally tolerated statin therapy in ASCVD. In very high-risk ASCVD individuals who are already under statin therapy and remain an increased LDL-C level (more than 70mg/dL); clinicians should then initiate additional non-statin therapy such as ezetimibe. Furthermore, individuals on maximally tolerated statin along with ezetimibe, a PCSK9 inhibitor should then be considered. Ezetimibe is preferred before initiating a PCSK9 inhibitor due to its cost and convenience. Begin high-intensity statin therapy despite 10-year ASCVD risk in severe hypercholesterolemia( LDL-C level greater than or equal to 190 mg/dL ). Start moderate-intensity statin therapy regardless of 10-year ASCVD risk in 40 to 75-year-old diabetic patients with a level of LDL-C greater than or equal to 70 mg/dL; for those non-diabetic patients with a level of LDL-C greater than or equal to 70 mg/dL and a 10-year ASCVD risk more than 7.5%, consider a moderate-intensity statin. Statin Intensity
Moderate-intensity statin therapy is expected to have a 30 to 50 percent LDL-C reduction, as following,
High-intensity statin therapy is expected to have a greater than or equal to 50 percent LDL-C reduction, as following,
In most of the cases, do not intensify statin therapy for patients who are on moderate-intensity statin therapy. The efficacy of statin therapy should undergo evaluation in six to eight weeks after the initiation. Statin therapy management should take place when statin-induced muscle adverse events, elevated aminotransferase, or renal dysfunction such as proteinuria have developed. However, routine monitoring of serum creatine kinase (CK) levels is not currently a reocmmendation for patients on statins. For medical practitioners, obtaining a baseline CK level should be considered before initiating statin therapy. Education on lifestyle modification, medication compliance, and awareness of new onset of muscle discomforts or weakness is crucial.
|||Friedewald WT,Levy RI,Fredrickson DS, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical chemistry. 1972 Jun; [PubMed PMID: 4337382]|
|||Catapano AL,Graham I,De Backer G,Wiklund O,Chapman MJ,Drexel H,Hoes AW,Jennings CS,Landmesser U,Pedersen TR,Reiner Ž,Riccardi G,Taskinen MR,Tokgozoglu L,Monique Verschuren WM,Vlachopoulos C,Wood DA,Luis Zamorano J,Cooney MT, 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Revista espanola de cardiologia (English ed.). 2017 Feb; [PubMed PMID: 29389351]|
|||Grundy SM,Stone NJ,Bailey AL,Beam C,Birtcher KK,Blumenthal RS,Braun LT,de Ferranti S,Faiella-Tommasino J,Forman DE,Goldberg R,Heidenreich PA,Hlatky MA,Jones DW,Lloyd-Jones D,Lopez-Pajares N,Ndumele CE,Orringer CE,Peralta CA,Saseen JJ,Smith SC Jr,Sperling L,Virani SS,Yeboah J, 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2018 Nov 10; [PubMed PMID: 30586774]|
|||Meeusen JW,Snozek CL,Baumann NA,Jaffe AS,Saenger AK, Reliability of Calculated Low-Density Lipoprotein Cholesterol. The American journal of cardiology. 2015 Aug 15; [PubMed PMID: 26059865]|
|||Martin SS,Blaha MJ,Elshazly MB,Toth PP,Kwiterovich PO,Blumenthal RS,Jones SR, Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA. 2013 Nov 20; [PubMed PMID: 24240933]|
|||Zilversmit DB, Atherogenesis: a postprandial phenomenon. Circulation. 1979 Sep; [PubMed PMID: 222498]|
|||Kolovou GD,Anagnostopoulou KK,Daskalopoulou SS,Mikhailidis DP,Cokkinos DV, Clinical relevance of postprandial lipaemia. Current medicinal chemistry. 2005; [PubMed PMID: 16101498]|
|||Nordestgaard BG,Benn M,Schnohr P,Tybjaerg-Hansen A, Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007 Jul 18; [PubMed PMID: 17635890]|
|||Duerden M,O'Flynn N,Qureshi N, Cardiovascular risk assessment and lipid modification: NICE guideline. The British journal of general practice : the journal of the Royal College of General Practitioners. 2015 Jul; [PubMed PMID: 26120133]|
|||Herink M,Ito MK, Medication Induced Changes in Lipid and Lipoproteins 2000; [PubMed PMID: 26561699]|
|||Doran B,Guo Y,Xu J,Weintraub H,Mora S,Maron DJ,Bangalore S, Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III). Circulation. 2014 Aug 12; [PubMed PMID: 25015340]|
|||Ford ES,Li C,Zhao G,Mokdad AH, Concentrations of low-density lipoprotein cholesterol and total cholesterol among children and adolescents in the United States. Circulation. 2009 Mar 3; [PubMed PMID: 19221218]|
|||Gooding HC,Rodday AM,Wong JB,Gillman MW,Lloyd-Jones DM,Leslie LK,de Ferranti SD, Application of Pediatric and Adult Guidelines for Treatment of Lipid Levels Among US Adolescents Transitioning to Young Adulthood. JAMA pediatrics. 2015 Jun; [PubMed PMID: 25845026]|
|||Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011 Dec; [PubMed PMID: 22084329]|
|||D'Agostino RB Sr,Vasan RS,Pencina MJ,Wolf PA,Cobain M,Massaro JM,Kannel WB, General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008 Feb 12; [PubMed PMID: 18212285]|
|||Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart (British Cardiac Society). 2014 Apr; [PubMed PMID: 24667225]|
|||Fredrickson DS, An international classification of hyperlipidemias and hyperlipoproteinemias. Annals of internal medicine. 1971 Sep; [PubMed PMID: 5568160]|
|||Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001 May 16; [PubMed PMID: 11368702]|
|||Sacks FM,Pfeffer MA,Moye LA,Rouleau JL,Rutherford JD,Cole TG,Brown L,Warnica JW,Arnold JM,Wun CC,Davis BR,Braunwald E, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. The New England journal of medicine. 1996 Oct 3; [PubMed PMID: 8801446]|
|||Baigent C,Blackwell L,Emberson J,Holland LE,Reith C,Bhala N,Peto R,Barnes EH,Keech A,Simes J,Collins R, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (London, England). 2010 Nov 13; [PubMed PMID: 21067804]|
|||LaRosa JC,Grundy SM,Waters DD,Shear C,Barter P,Fruchart JC,Gotto AM,Greten H,Kastelein JJ,Shepherd J,Wenger NK, Intensive lipid lowering with atorvastatin in patients with stable coronary disease. The New England journal of medicine. 2005 Apr 7; [PubMed PMID: 15755765]|
|||Stamler J,Wentworth D,Neaton JD, Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986 Nov 28; [PubMed PMID: 3773199]|
|||Gregg EW,Cheng YJ,Cadwell BL,Imperatore G,Williams DE,Flegal KM,Narayan KM,Williamson DF, Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA. 2005 Apr 20; [PubMed PMID: 15840861]|
|||Mihaylova B,Emberson J,Blackwell L,Keech A,Simes J,Barnes EH,Voysey M,Gray A,Collins R,Baigent C, The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet (London, England). 2012 Aug 11; [PubMed PMID: 22607822]|
|||Zhang J,Xu J,Wang J,Wu C,Xu Y,Wang Y,Deng F,Wang Z,Chen X,Wu M,Chen Y, Prognostic Usefulness of Serum Cholesterol Efflux Capacity in Patients With Coronary Artery Disease. The American journal of cardiology. 2016 Feb 15; [PubMed PMID: 26718234]|
|||Grundy SM,Stone NJ,Bailey AL,Beam C,Birtcher KK,Blumenthal RS,Braun LT,de Ferranti S,Faiella-Tommasino J,Forman DE,Goldberg R,Heidenreich PA,Hlatky MA,Jones DW,Lloyd-Jones D,Lopez-Pajares N,Ndumele CE,Orringer CE,Peralta CA,Saseen JJ,Smith SC Jr,Sperling L,Virani SS,Yeboah J, 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2018 Nov 8; [PubMed PMID: 30423393]|